UA130650C2 - Сіль і кристалічні форми інгібітора активін-рецептороподібної кінази - Google Patents

Сіль і кристалічні форми інгібітора активін-рецептороподібної кінази

Info

Publication number
UA130650C2
UA130650C2 UAA202200733A UAA202200733A UA130650C2 UA 130650 C2 UA130650 C2 UA 130650C2 UA A202200733 A UAA202200733 A UA A202200733A UA A202200733 A UAA202200733 A UA A202200733A UA 130650 C2 UA130650 C2 UA 130650C2
Authority
UA
Ukraine
Prior art keywords
salt
compound
peaks
diffraction pattern
sun
Prior art date
Application number
UAA202200733A
Other languages
English (en)
Ukrainian (uk)
Inventor
Клер Медендорп
Дебра Мазаік
Дебра Мазаик
Гордон Вілкі
Гордон Вилки
Джошуа Д. Ветціг
Джошуа Д. Ветциг
Брайан Генріх
Брайан Генрих
Лорен Макечерн
Домінік Сігел
Доминик Сигел
Харальд Омер
Стівен С. Джонстон
Стивен С. Джонстон
Original Assignee
Блюпрінт Медісінс Корпорейшн
Блюпринт Медисинс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Блюпрінт Медісінс Корпорейшн, Блюпринт Медисинс Корпорейшн filed Critical Блюпрінт Медісінс Корпорейшн
Publication of UA130650C2 publication Critical patent/UA130650C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UAA202200733A 2019-08-13 2020-08-12 Сіль і кристалічні форми інгібітора активін-рецептороподібної кінази UA130650C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
PCT/US2020/045847 WO2021030386A1 (en) 2019-08-13 2020-08-12 Salt and crystal forms of an activin receptor-like kinase inhibitor

Publications (1)

Publication Number Publication Date
UA130650C2 true UA130650C2 (uk) 2026-04-08

Family

ID=72193669

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202200733A UA130650C2 (uk) 2019-08-13 2020-08-12 Сіль і кристалічні форми інгібітора активін-рецептороподібної кінази

Country Status (15)

Country Link
US (1) US20220281879A1 (cg-RX-API-DMAC10.html)
EP (1) EP4013757A1 (cg-RX-API-DMAC10.html)
JP (2) JP7775186B2 (cg-RX-API-DMAC10.html)
KR (1) KR102967623B1 (cg-RX-API-DMAC10.html)
CN (2) CN114222745B (cg-RX-API-DMAC10.html)
AU (1) AU2020328534B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002597A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146701A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022001450A2 (cg-RX-API-DMAC10.html)
IL (1) IL290482A (cg-RX-API-DMAC10.html)
JO (1) JOP20220014A1 (cg-RX-API-DMAC10.html)
MX (2) MX2022001741A (cg-RX-API-DMAC10.html)
TW (1) TWI870440B (cg-RX-API-DMAC10.html)
UA (1) UA130650C2 (cg-RX-API-DMAC10.html)
WO (1) WO2021030386A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2026161341A1 (en) * 2025-01-21 2026-07-30 Blueprint Medicines Corporation Drug product formulations of fidrisertib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3442977T3 (fi) * 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Also Published As

Publication number Publication date
TWI870440B (zh) 2025-01-21
KR20220052955A (ko) 2022-04-28
AU2020328534A1 (en) 2022-03-17
JP2022544272A (ja) 2022-10-17
JP2025148406A (ja) 2025-10-07
JOP20220014A1 (ar) 2023-01-30
MX2022001741A (es) 2022-03-11
US20220281879A1 (en) 2022-09-08
WO2021030386A1 (en) 2021-02-18
EP4013757A1 (en) 2022-06-22
CN114222745A (zh) 2022-03-22
AU2020328534B2 (en) 2026-04-30
BR112022002597A2 (pt) 2022-07-05
CN119638704A (zh) 2025-03-18
JP7775186B2 (ja) 2025-11-25
TW202120509A (zh) 2021-06-01
CO2022001450A2 (es) 2022-05-31
CN114222745B (zh) 2025-03-25
MX2024014312A (es) 2024-12-06
KR102967623B1 (ko) 2026-05-21
CA3146701A1 (en) 2021-02-18
IL290482A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
CN114195799B (zh) 吡嗪类衍生物及其在抑制shp2中的应用
ES2550771T3 (es) Sal de bismesilato etexilato de dabigatrán, formas en estado sólido y proceso para la preparación de las mismas
ES2685819T3 (es) Formas mórficas de ésteres de hexadeciloxipropil-fosfonato
JP7775186B2 (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
WO1998039325A1 (en) 4,4-difluoro-2,3,4,5-tetrahydro-1h-1-benzazepine derivatives and drug compositions containing them
BR112014022790B1 (pt) Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo
CA3154079A1 (en) Therapeutic conjugates
CN111566102A (zh) 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶
US8946249B2 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
US20240228500A1 (en) Therapeutic conjugates
CA3184979A1 (en) Immunomodulator
EA031569B1 (ru) Солевые и кристаллические формы ингибитора plk-4
JP2021526156A (ja) ジメチルホスフィンオキシド化合物
CN111757877A (zh) 甲基内酰胺环化合物及其药物用途
JP2021512964A (ja) グランザイムb指向性画像化および治療
JP2019512542A (ja) 結晶塩形態
BR112020016205A2 (pt) Formas cocristalinas de prolina e de análogo de novobiocina
US20250179049A1 (en) Salts of heterocyclic inhibitors of monocarboxylate transporter 4 for the treatment of disease
CN104093703B (zh) Mglu 2/3激动剂
RU2809634C2 (ru) Соединение с метиллактамным кольцом и его применение в фармацевтике
BRPI0620526A2 (pt) sal de acetato e método para alcançar um efeito em um paciente
HK40069001A (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
HK40117473A (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
HK40069001B (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
TW202327576A (zh) 吡咯烷類化合物的鹽、晶型及其製備方法